Literature DB >> 16830371

Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma.

Frederic Di Fiore1, Stephane Lecleire, Olivier Rigal, Marie-Pierre Galais, Emmanuel Ben Soussan, Isabelle David, Bernard Paillot, Jacques-Henri Jacob, Pierre Michel.   

Abstract

AIM: The aim of the study was to evaluate the predictive factors of survival in patients with locally advanced squamous cell esophageal carcinoma (LASCOC) treated with definitive chemoradiotherapy (CRT) regimen based on the 5FU/CDDP combination.
METHODS: All patients with LASCOC treated with a definitive CRT using the 5FU/CDDP combination between 1994 and 2000 were retrospectively included. Clinical complete response (CCR) to CRT was assessed by esophageal endoscopy and CT-scan 2 mo after CRT completion. Prognostic factors of survival were assessed using univariate and multivariate analysis by the Cox regression model.
RESULTS: A total of 116 patients were included in the study. A CCR to CRT was observed in 86/116 (74.1%). The median survival was 20 mo (range 2-114) and the 5-year survival was 9.4%. Median survival of responder patients to CRT was 25 mo (range 3-114) as compared to 9 mo (range 2-81) in non-responder patients (P < 0.001). In univariate analysis, survival was associated with CCR (P < 0.001), WHO performance status < 2 (P = 0.01), tumour length < 6 cm (P = 0.045) and weight loss < 10% was in limit of significance (P = 0.053). In multivariate analysis, survival was dependant to CCR (P < 0.0001), weight loss < 10% (P = 0.034) and WHO performance < 2 (P = 0.046).
CONCLUSION: Our results suggest that survival in patients with LASCOC treated with definitive CRT was correlated to CCR, weight loss and WHO performance status.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16830371      PMCID: PMC4087370          DOI: 10.3748/wjg.v12.i26.4185

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  35 in total

1.  Cancer incidence and mortality in France in 1975-95.

Authors:  F Ménégoz; R J Black; P Arveux; V Magne; J Ferlay; A Buémi; P M Carli; G Chapelain; J Faivre; M Gignoux; P Grosclaude; J Mace-Lesec'h; N Raverdy; P Schaffer
Journal:  Eur J Cancer Prev       Date:  1997-10       Impact factor: 2.497

2.  [Concurrent concentrated radio-chemotherapy of epidermoid cancer of the esophagus. Long-term results of a phase II national multicenter trial in 122 non-operable patients (FFCD 8803)].

Authors:  J F Seitz; C Milan; M Giovannini; F Dumas; J M Cauvin; T Conroy; E François; P Renard; A Votte-Lambert; B Paillot; L Bedenne
Journal:  Gastroenterol Clin Biol       Date:  2000-02

3.  Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.

Authors:  A Herskovic; K Martz; M al-Sarraf; L Leichman; J Brindle; V Vaitkevicius; J Cooper; R Byhardt; L Davis; B Emami
Journal:  N Engl J Med       Date:  1992-06-11       Impact factor: 91.245

4.  Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group.

Authors:  J S Cooper; M D Guo; A Herskovic; J S Macdonald; J A Martenson; M Al-Sarraf; R Byhardt; A H Russell; J J Beitler; S Spencer; S O Asbell; M V Graham; L L Leichman
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

5.  Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus.

Authors:  B D Minsky; D Neuberg; D P Kelsen; T M Pisansky; R J Ginsberg; T Pajak; M Salter; A B Benson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-02-01       Impact factor: 7.038

6.  Neoadjuvant concurrent chemoradiotherapy followed by definitive high-dose radiotherapy or surgery for operable thoracic esophageal carcinoma.

Authors:  M Murakami; Y Kuroda; Y Okamoto; K Kono; E Yoden; F Kusumi; K Hajiro; S Matsusue; H Takeda
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-03-15       Impact factor: 7.038

7.  Radiotherapy alone compared with radiotherapy and chemotherapy in patients with squamous cell carcinoma of the esophagus.

Authors:  S P Reddy; T Lad; M Mullane; F Rosen; R Carroll; J E Marks
Journal:  Am J Clin Oncol       Date:  1995-10       Impact factor: 2.339

8.  Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study.

Authors:  B H Burmeister; J W Denham; M O'Brien; G G Jamieson; P G Gill; P Devitt; E Yeoh; C S Hamilton; S P Ackland; D S Lamb
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-07-15       Impact factor: 7.038

9.  Nonoperative therapy for squamous-cell cancer of the esophagus.

Authors:  L Leichman; A Herskovic; C G Leichman; P B Lattin; Z Steiger; E Tapazoglou; J C Rosenberg; A Arbulu; I Asfaw; J Kinzie
Journal:  J Clin Oncol       Date:  1987-03       Impact factor: 44.544

10.  Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report.

Authors:  A A Forastiere; M B Orringer; C Perez-Tamayo; S G Urba; M Zahurak
Journal:  J Clin Oncol       Date:  1993-06       Impact factor: 44.544

View more
  28 in total

1.  Low expression of IGFBP-3 predicts poor prognosis in patients with esophageal squamous cell carcinoma.

Authors:  Lei Zhao; Li-Ru He; Rui Zhang; Mu-Yan Cai; Yi-Ji Liao; Dong Qian; Mian Xi; Yi-Xin Zeng; Dan Xie; Meng-Zhong Liu
Journal:  Med Oncol       Date:  2011-12-14       Impact factor: 3.064

2.  Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma.

Authors:  Jin Lv; Xiu Feng Cao; Bin Zhu; Lv Ji; Lei Tao; Dong Dong Wang
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

3.  Shifting practice in definitive chemoradiation for localized esophageal cancer.

Authors:  X M Qu; J J Biagi; W M Hopman; A Mahmud
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677

4.  Percutaneous radiological gastrostomy in esophageal cancer patients: a feasible and safe access for nutritional support during multimodal therapy.

Authors:  Williams Tessier; Guillaume Piessen; Nicolas Briez; Arianna Boschetto; Géraldine Sergent; Christophe Mariette
Journal:  Surg Endosc       Date:  2012-09-07       Impact factor: 4.584

5.  Full costs of dispensing and administering fluorouracil chemotherapy for outpatients: A microcosting study.

Authors:  Dong-Churl Suh; Christopher A Powers; Joseph A Barone; HyunChul Shin; Jinweon Kwon; Susan Goodin
Journal:  Res Social Adm Pharm       Date:  2010-09

6.  Elective nodal irradiation or involved-field irradiation in definitive chemoradiotherapy for esophageal squamous cell cancer: a retrospective analysis in clinical N0 patients.

Authors:  Y Sun; X L Zhang; Q F Mao; Y H Liu; L Kong; M H Li
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

Review 7.  Important aspects of nutrition in children with cancer.

Authors:  Jacqueline Bauer; Heribert Jürgens; Michael C Frühwald
Journal:  Adv Nutr       Date:  2011-03-10       Impact factor: 8.701

8.  Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma.

Authors:  Sonia A Duffy; David L Ronis; Scott McLean; Karen E Fowler; Stephen B Gruber; Gregory T Wolf; Jeffrey E Terrell
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

9.  A six-CpG panel with DNA methylation biomarkers predicting treatment response of chemoradiation in esophageal squamous cell carcinoma.

Authors:  Wei-Lun Chang; Wu-Wei Lai; I-Ying Kuo; Chien-Yu Lin; Pei-Jung Lu; Bor-Shyang Sheu; Yi-Ching Wang
Journal:  J Gastroenterol       Date:  2016-09-26       Impact factor: 7.527

10.  Impact of Sarcopenia in Patients with Unresectable Locally Advanced Esophageal Cancer Receiving Chemoradiotherapy.

Authors:  Sho Sato; Chikara Kunisaki; Hideaki Suematsu; Yusaku Tanaka; Hiroshi Miyamoto; Takashi Kosaka; Norio Yukawa; Kuniya Tanaka; Kei Sato; Hirotoshi Akiyama; Itaru Endo
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.